Role of MTCC1325 in membrane-bound transport ATPases system in Alzheimer's disease-induced rat brain.

Alzheimer's disease (AD) is a neurodegenerative disorder, clinically characterized by memory dysfunction and progressive loss of cognition. No curative therapeutic or drug is available for the complete cure of this disease. The present study was aimed to evaluate the efficacy of MTCC1325 in ATPases activity in the selected brain regions of rats induced with Alzheimer's. For the study, 48 healthy Wistar rats were divided into four groups: group I as control group, group II as AD model (AD induced by intraperitoneal injection of D-Galactose, 120 mg/kg body weight for 6 weeks), group III as normal control rats which were orally administered only with MTCC1325 for 60 days, and group IV where the AD-induced rats simultaneously received oral treatment of MTCC1325 (10ml/kg body weight, 12×10 CFU/mL) for 60 days. The well known membrane bound transport enzymes including Na, K-ATPases, Ca-ATPases, and Mg-ATPases were assayed in the selected brain regions of hippocampus and cerebral cortex in all four groups of rats at selected time intervals. Chronic injection of D-Galactose caused lipid peroxidation, oxidative stress, and mitochondrial dysfunction leading to the damage of neurons in the brain, finally bringing a significant decrease (-20%) in the brain total membrane bound ATPases over the controls. Contrary to this, treatment of AD-induced rats with MTCC1325 reverted all the constituents of ATPase enzymes to near normal levels within 30 days. MTCC1325 exerted a beneficial action on the entire ATPases system in AD-induced rat brain by delaying neurodegeneration.